Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan.
The company needs to announce their own plan to keep themselves away from any NYSE listing issues. On their last quarter earning report ,Steven Shallcross, Interim Chief Executive Officer and Chief Financial Officer mentioned very clearly about their strategy for the year of 2018. They need to establish the optimal clinical protocol for SYN-004 phase 3 study . Our team has tracked SYN since November 2017 , and we can clearly see a downtrend for the stock price . The chart started to receive some positive momentum signs a week ago , and the stock traded above its average volume . With possible news about their plan to stay in compliance with NYSE requirements , an uptrend pathway could establish a perfect opportunity to regain the value of this stock. We do not want to be over optimistic about what they will announce , but for the long term--especially before the end of the first half of 2018--we are expecting more investors to make their decision about this stock, if the outcome of discussing between Synthetic and the FDA for the regulatory pathway towards marketing approval is going well . Their goal also is to initiate phase 3 clinical trial by 2019 . Our team rate for this stock now a day is strong hold /Buy For the next 20 days . If you are interested to know more details about our opinion for this stock ( The good entry and the price target ) and other stocks ,please Join our mail list today .
Important note: We are just a small team of independent traders and uncertified technical chart analysis, and we do not have any insider trading or connection with any company related to any stocks we mentioned. You own your decision to buy, hold or sell any of them.
Pay attention : If you would like to receive our last awesome picks for a day, swing and long trade, please subscribe to our mailing list .
Share on Facebook
Share on Twitter
I'm busy working on my blog posts. Watch this space!